In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...
Read More
In a nutshell The aim of this study was to evaluate the safety and effectiveness of combining androgen deprivation therapy (ADT) with docetaxel (Taxotere) plus prednisone (Deltasone) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The study found that this combination improved the outcomes of these...
Read MoreIn a nutshell This study compared 6-month and 18-month courses of hormonal anti-androgen treatment and radiotherapy (RT) in patients with locally advanced prostate cancer (LAPC). The results showed that 18-month treatment was most effective, especially when used with high dose brachytherapy RT. Some background Androgens (such as testosterone) are...
Read MoreIn a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...
Read MoreIn a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...
Read MoreIn a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...
Read MoreIn a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...
Read MoreIn a nutshell This phase 2b trial will evaluate ModraDoc006 (MOD) in patients with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes will be the objective response rate (ORR). This trial is recruiting at a number of locations in the US. The details Metastatic castration-resistant prostate cancer (mCRPC) is...
Read MoreIn a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...
Read MoreIn a nutshell This study compared the effectiveness of current treatment options for high-risk prostate cancer (PCa). It found that RP is the preferred treatment option for these patients. Some background Prostate surgery (RP) is a common treatment option for high-risk PCa. Radiation therapy (RT), androgen deprivation therapy...
Read MoreIn a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) in metastatic prostate cancer. This study found that enzalutamide was associated with longer progression-free and overall survival compared to standard of care. Some background Enzalutamide is an anti-androgen medication....
Read MoreIn a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to...
Read More
